# Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

> **NCT00921375** · PHASE3 · COMPLETED · sponsor: **Virchow Group** · enrollment: 100 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** TULY

## Key facts

- **NCT ID:** NCT00921375
- **Lead sponsor:** Virchow Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-12
- **Final completion:** 2012-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00921375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00921375, "Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00921375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*